Medical treatment characteristics
| Crohn’s disease, n=269 (%) | Ulcerative colitis, n=196 (%) | |
| Mesalazine | ||
| Current | 26 (9.7) | 154 (78.6) |
| Previous | 30 (8.1) | 23 (11.7) |
| Thiopurine | ||
| Current | 72 (26.8) | 51 (26) |
| Previous | 106 (37.9) | 25 (12.8) |
| Methotrexate | ||
| Current | 9 (3) | 1 (0.5) |
| Previous | 26 (8.8) | 4 (2) |
| Infliximab | ||
| Current | 50 (18.6) | 10 (5.1) |
| Previous | 56 (18.9) | 9 (4.6) |
| Adalimumab | ||
| Current | 42 (14.2) | 4 (2) |
| Previous | 30 (10.1) | 4 (2) |
| Vedolizumab | ||
| Current | 6 (2) | 3 (1.5) |
| Previous | 2 (0.7) | 1 (0.5) |
| Current steroid | 29 (9.8) | 29 (14.8) |